» Articles » PMID: 34577827

Pilot Study on the Use of the "Monocyte-Rich" Platelet-Rich Plasma in Combination with 1927 Nm Fractional and 308 Nm Excimer Lasers for the Treatment of Vitiligo

Overview
Publisher MDPI
Specialty General Medicine
Date 2021 Sep 28
PMID 34577827
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

: Vitiligo is an acquired chronic and idiopathic skin disorder, characterized by selective loss of melanocytes and resulting in a cutaneous depigmentation. Treatment for vitiligo remains a challenge for dermatologists; thus, it is frustrating both for physicians and patients. The objective of this study was to evaluate a combination treatment characterized by the use of a leukocyte-rich platelet-rich plasma, which is particularly rich in monocytes (defined here as monocyte-rich PRP), in combination with a 1927 nm fraxel laser and a 308 nm excimer laser. : Treatment with monocyte-rich PRP combined with 1927 nm fraxel laser and 308 nm excimer laser was performed in nine sessions in 80 days and the median follow-up of the patients was 10 months. A total of 27 Caucasian patients were included in the present study. The median age of patients was 41 years, ranging between 20 and 69 years. : A re-pigmentation occurred in 16 cases (59%) with a reduction of the Vitiligo Extent Score (VES) and absence of re-pigmentation in untreated areas. Performing a rank correlation between VES and re-pigmentation in the treated areas, we found that there was a significant correlation ( < 0.0001). The presence of progressive vitiligo ( = 0.1) and the anatomic areas ( = 0.1) did not influence the treatment. Untreated areas did not show any improvement of the depigmented lesions, except in one case ( < 0.0001). : in this report, we show for the first time how PRP rich in monocytes, in combination with laser therapies, gives a long therapeutic response, which persists even after 10 months of follow-up.

Citing Articles

A scoping review of the extent of the clinical research on the vitiligo extent score.

Orozco-Jimenez S, Rueda-Galvis P, Builes-Montano C, Arango-Salgado A Arch Dermatol Res. 2025; 317(1):498.

PMID: 40009214 DOI: 10.1007/s00403-024-03778-4.


Adult-Onset Linear Morphea () of the Face Successfully Treated with Photoactivated Low-Temperature Platelet-Rich Plasma: A Valid Therapeutic Option.

Mercuri S, Di Nicola M, Bianchi V, Paolino G Medicina (Kaunas). 2023; 59(6).

PMID: 37374318 PMC: 10303987. DOI: 10.3390/medicina59061114.


Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?.

Wikramanayake T, Haberland N, Akhundlu A, Laboy Nieves A, Miteva M Curr Oncol. 2023; 30(4):3609-3626.

PMID: 37185388 PMC: 10137043. DOI: 10.3390/curroncol30040275.

References
1.
Devereaux J, Dargahi N, Fraser S, Nurgali K, Kiatos D, Apostolopoulos V . Leucocyte-Rich Platelet-Rich Plasma Enhances Fibroblast and Extracellular Matrix Activity: Implications in Wound Healing. Int J Mol Sci. 2020; 21(18). PMC: 7556022. DOI: 10.3390/ijms21186519. View

2.
Kadry M, Tawfik A, Abdallah N, Badawi A, Shokeir H . Platelet-rich plasma versus combined fractional carbon dioxide laser with platelet-rich plasma in the treatment of vitiligo: a comparative study. Clin Cosmet Investig Dermatol. 2018; 11:551-559. PMC: 6231433. DOI: 10.2147/CCID.S178817. View

3.
Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy J, Lacour J . Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004; 140(9):1065-9. DOI: 10.1001/archderm.140.9.1065. View

4.
Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q . Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo--a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013; 29(1):27-33. DOI: 10.1111/phpp.12015. View

5.
Alhowaish A, Dietrich N, Onder M, Fritz K . Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci. 2012; 28(3):1035-41. DOI: 10.1007/s10103-012-1185-1. View